Eli Lilly and Company $LLY Shares Sold by E. Ohman J or Asset Management AB

Key Points

• E. Ohman J or Asset Management AB has reduced its holdings in Eli Lilly and Company by 57.0%, selling 53,163 shares, and now owns 40,033 shares worth approximately $31.2 million.
• Eli Lilly reported $6.31 earnings per share for the recent quarter, exceeding analysts' expectations of $5.59, with a revenue increase of 37.6% year-over-year, totaling $15.56 billion.
• The company declared a quarterly dividend of $1.50 per share, reflecting an annualized rate of $6.00 and a dividend yield of 0.8%.

E. Ohman J or Asset Management AB reduced its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 57.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,033 shares of the company's stock after selling 53,163 shares during the period. E. Ohman J or Asset Management AB's holdings in Eli Lilly and Company were worth $31,207,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. WestEnd Advisors LLC boosted its holdings in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter valued at $27,000. Citizens National Bank Trust Department boosted its holdings in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company in the first quarter valued at $40,000. Finally, Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at $43,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $7.13 during trading on Monday, hitting $748.26. 2,787,993 shares of the stock were exchanged, compared to its average volume of 3,436,359. The company has a fifty day moving average price of $740.54 and a two-hundred day moving average price of $774.30. The company has a market cap of $708.20 billion, a PE ratio of 48.91, a P/E/G ratio of 1.05 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $939.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company's dividend payout ratio is currently 39.22%.

Insider Buying and Selling

In other news, Director J Erik Fyrwald acquired 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 over the last quarter. Company insiders own 0.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on LLY shares. Leerink Partners reiterated a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Guggenheim decreased their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Finally, Cantor Fitzgerald decreased their price target on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $941.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.